Please ensure Javascript is enabled for purposes of website accessibility

3 Ways AI Is Changing Medicine

By Danny Vena - Updated Sep 24, 2017 at 7:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Artificial intelligence isn't just for self-driving cars and virtual assistants. Medicine is finding new uses for the nascent technology.

Recent developments in artificial intelligence (AI) are turning science fiction into science fact -- and deep learning is at the heart of these advances. These AI systems have the ability to sift through scores of data, recognize patterns, and detect differences that might be imperceptible to humans. Some applications are already achieving remarkable results.

One of the more promising areas of research seeking to tap these capabilities is medicine. Companies like Alphabet Inc. (GOOGL -1.34%) (GOOG -1.29%), International Business Machines (IBM -0.91%), and NVIDIA Corporation (NVDA -2.51%) are using the predictive power of AI to provide doctors with additional tools to fight disease.

Doctors and nurses talking by window in hospital.

Artificial intelligence is giving physicians new tools to save lives. Image source: Getty Images.

Immunotherapy to fight cancer

Two-year-old start-up Gritstone Oncology has attracted both attention and investment from Alphabet Inc.'s Google Ventures. The biotech company has been studying the use of deep learning to develop highly targeted immunotherapies, which recruit the body's immune system to fight cancer. Immunotherapy has produced significant positive results in about 20% of cancer patients but has been unsuccessful for the remainder. Gritstone is using AI to analyze tumors at the molecular level and narrow the list of immunotherapies to match them with specific patients. 

Pharmaceutical giant Pfizer Inc. (PFE 3.59%) is collaborating with IBM's Watson cognitive AI supercomputer to discover new drugs and approaches for immunotherapy. Watson's consumed 25 million Medline abstracts, over a million articles from medical journals, records from 4 million patients, as well as every drug patent since 1861. The system is regularly updated with the latest available medical research data. What began as a pilot program became a full-fledged partnership when Watson suggested a novel treatment that had recently been recommended by Pfizer's team of researchers, and that therapy is currently undergoing trials.

Diabetes and retinal blindness

One of the major causes of blindness is damage to the retina resulting from diabetes. Known as diabetic retinopathy (DR), the condition occurs in more than 40% of U.S. patients with the disease. There may be no symptoms in the initial stages, so early detection is critical. Unfortunately, there is currently a shortage of ophthalmologists qualified to diagnose the condition. 

Researchers at Alphabet's Google Brain have developed an AI system that can examine images of the retina and detect DR as well as human ophthalmologists, according to a paper published in the Journal of the American Medical Association. The system exceeded the standards set by the National Institutes of Health for accuracy and precision. This technology can be used to provide screening for the condition in the absence of qualified ophthalmologists, preventing blindness in an untold number of patients at risk. 

Detect heart disease and predict heart attacks

Verily, a subsidiary of Alphabet's Google, was able to use images of the retina to detect new signals of heart disease risk. Using data from nearly 300,000 patients, the AI system was able to detect indicators in retinal images of age, gender, blood pressure, and blood sugar, and use that information to estimate the risk of heart failure. The researchers published a paper claiming to have achieved accuracy levels equivalent to the results obtained using blood tests, though that paper has not yet been subjected to peer review. 

HeartFlow is medical technology company that is using graphics processors from NVIDIA Corporation (NVDA -2.51%) and deep learning to create 3D mapping used to provide early detection of heart disease. Current methods to diagnose the condition involve a costly and invasive medical procedure. HeartFlow's alternative uses CT scans and deep learning to create a 3D model of the heart that can provide detailed representations of blood flow and blockages. Providing a more accurate diagnosis while eliminating the necessity of a costly procedure can reduce the associated healthcare costs by 25%. 

Just what the doctor ordered

These recent developments provide insight into the future of AI-assisted medicine. AI is still in its infancy, and researchers have only scratched the surface in terms of the ways that AI will revolutionize medical care.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

International Business Machines Corporation Stock Quote
International Business Machines Corporation
IBM
$128.48 (-0.91%) $-1.18
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOGL
$2,178.16 (-1.34%) $-29.52
NVIDIA Corporation Stock Quote
NVIDIA Corporation
NVDA
$166.94 (-2.51%) $-4.30
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOG
$2,186.26 (-1.29%) $-28.65
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.47 (3.59%) $1.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.